AnaptysBio, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of AnaptysBio, Inc.'s financial disclosures and regulatory filings, offering insights into the company's performance and strategic decisions. It highlights key events such as earnings reports, corporate presentations, and conference transcripts, detailing the company's planned spin-off into biopharma and royalty entities, Jemperli royalty growth, and advancement of its clinical pipeline. Investors can use these resources to inform their investment decisions regarding ANAPTYSBIO, INC.
AnaptysBio, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of financial disclosures and regulatory filings for AnaptysBio, Inc. The documents detail the company's strategic decisions, including its planned spin-off into biopharma and royalty entities, quarterly earnings, and presentations from various healthcare conferences, offering insights into its performance, pipeline advancements, and future outlook. Key themes include the growth of Jemperli royalties and progress in clinical trials for immunology assets.
[144] ANAPTYSBIO, INC SEC Filing
This article details an SEC Form 144 filing by AnaptysBio, Inc. (ANAB) concerning a proposed sale of securities. The document indicates a neutral filing impact and sentiment, outlining the filer and issuer information, as well as details about the common stock to be sold by Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also includes information on the acquisition of these securities and states that no securities were sold in the past three months for the account of the person described.
Is AnaptysBio’s (ANAB) Index Exit and Office Sublease Quietly Reframing Its Strategic Focus?
AnaptysBio (ANAB) was recently removed from several Russell indices and entered a one-year sublease agreement for its San Diego facility. These actions suggest a strategic shift involving optimized real estate commitments and a reframing of its investment narrative. Investors should consider how these developments, alongside ongoing restructuring, clinical readouts, and litigation, influence the company's future value.
Price to book forward of AnaptysBio, Inc. – NASDAQ:ANAB
The article focuses on the "Price to book forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It provides a view of this financial indicator on the TradingView platform, noting that the market is closed and no trades have occurred for the stock.
Enterprise value to EBITDA forward of AnaptysBio, Inc. – NASDAQ:ANAB
The article provides the "Enterprise value to EBITDA forward" metric for AnaptysBio, Inc. (NASDAQ: ANAB). It appears to be a financial data snippet from TradingView, which offers various market tools and data for stocks, including detailed financial information.
Form 144 ANAPTYSBIO For: 29 June By Investing.com
This article announces the filing of Form 144 for ANAPTYSBIO (ANAB) on June 29. Form 144 is filed with the SEC when company insiders intend to sell restricted or controlled securities. The article provides the title, date, and company, indicating a standard regulatory filing notification.
Affiliate plans to sell 9,476 ANAB shares (NASDAQ: ANAB)
An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB) has filed a Form 144 to sell 9,476 shares acquired via a stock option exercise on June 29, 2026. The filing also details multiple common stock dispositions by Dennis Mulroy throughout May and June 2026, including specific share counts and gross proceeds from each sale. This indicates routine insider and affiliate transaction activity.
AnaptysBio (NASDAQ: ANAB) proxy details director votes and equity plan limits
AnaptysBio (NASDAQ: ANAB) is holding its annual stockholders meeting on August 11, 2026, where key items for vote include the election of two Class III directors, ratification of KPMG LLP as the auditor, an advisory Say-on-Pay vote for executive compensation, and an amendment to its 2017 Equity Incentive Plan. The proposed amendment would extend the plan's term by 10 years and introduce compensation caps for non-employee directors, without increasing the current share reserve. As of June 22, 2026, 29,608,481 common shares are outstanding and eligible to vote.
AnaptysBio, Inc.(NasdaqGS: ANAB) dropped from Russell Microcap Index
AnaptysBio, Inc. (ANAB) has been removed from the Russell Microcap Index. The company's recent activities include a change in its fiscal year-end, UBS adjusting its price target to $76 with a Buy rating, and reporting earnings for Q1 2026. AnaptysBio also recently appointed Chris Murphy as CFO and Owen Hughes to its board of directors.
AnaptysBio (ANAB) Draws Valuation Attention, Is The Market Already Pricing In Future Growth?
AnaptysBio (ANAB), a clinical stage biotech company, is drawing attention with its recent performance and current valuation. While its 7.3x Price-to-Sales ratio appears undervalued compared to industry peers, an estimated fair P/S ratio suggests it might be overvalued. A Discounted Cash Flow model, however, indicates the stock could be trading at a steep discount, highlighting a divergence in valuation perspectives for this equity.
Form 144 ANAPTYSBIO For: 26 June By Investing.com
Investing.com reported on a Form 144 filing for ANAPTYSBIO on June 26, 2026. The article primarily consists of the headline repeated several times and a timestamp, with no further details about the filing itself. It is surrounded by various market data, news headlines, and navigational links common to the Investing.com platform.
ANAB (NASDAQ) insider sells 10,000 shares; Mulroy made multiple May–June sales
A recent SEC Form 144 filing indicates an insider sale of 10,000 ANAB shares through a stock option exercise on June 26, 2026. The filing also details multiple prior sales by Dennis Mulroy in May and June 2026, including 35,000 shares for $1,848,750 and 20,000 shares for $1,153,014. These transactions involve reported sales and proceeds, though cash-flow counterparties and post-transaction holdings are not specified in the excerpt.
ANAB Forecast — Price Target — Prediction for 2027
This article provides a forecast for AnaptysBio, Inc. (ANAB) stock, including its current price of 64.75 USD, recent performance trends, and analyst price targets. Eight analysts have provided 1-year price forecasts, with a maximum estimate of 95.00 USD and a minimum of 70.00 USD. The article also covers ANAB's financial metrics, market capitalization, earnings reports, and volatility.
AnaptysBio, Inc. Actuals & Estimates (NASDAQ:ANAB)
This article provides an overview of AnaptysBio, Inc. (ANAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights the stock's recent increase of 5.81% in 24 hours and a 303.32% increase over the last year, with analysts projecting a price range of $70.00 to $95.00. The company's last reported earnings were -1.84 USD per share, missing estimates, while revenue exceeded expectations at $25.56 million.
AnaptysBio, Inc. Actuals & Estimates (BIVA:ANAB)
This article provides financial actuals and estimates for AnaptysBio, Inc. (ANAB) on the BIVA exchange, including analyst price targets, market capitalization, volatility, and historical earnings performance. It also details upcoming earnings dates and revenue projections, along with EBITDA and employee count.
ANAB Forecast — Price Target — Prediction for 2027
This article provides a forecast for AnaptysBio, Inc. (ANAB) stock, including analyst price targets and future predictions for 2027. It details the company's financial performance, such as recent earnings and revenue, market capitalization, employee count, and upcoming earnings report dates, while reiterating that the information is not investment advice.
AnaptysBio (NASDAQ: ANAB) subleases San Diego facility to First Tracks under master lease
AnaptysBio, Inc. has subleased 45,057 rentable square feet of its San Diego facility at 10770 Wateridge Circle to First Tracks Biotherapeutics. This sublease, which began on June 15, 2026, runs for 12 months with an option for First Tracks to extend until April 4, 2028, or for another 12 months. First Tracks will pay the same monthly rent and additional rent as AnaptysBio's master lease obligations, and AnaptysBio remains the primary obligor to the master landlord.
Director at AnaptysBio (NASDAQ: ANAB) receives 6,030 shares via RSUs
AnaptysBio director Renton Hollings received 6,030 shares of common stock after exercising 6,030 restricted stock units (RSUs) on June 15, 2026. This transaction was a compensation vesting event, not a market purchase or sale, and resulted in Hollings directly holding 10,995 shares of AnaptysBio. The RSUs vested 100% on the specified date, converting one-to-one into common stock without any cash consideration.
Eversept Partners LP Takes $5.86 Million Position in AnaptysBio, Inc. $ANAB
Eversept Partners LP has acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the fourth quarter, purchasing 120,927 shares valued at approximately $5.86 million, representing 0.44% of the company. This comes as other institutional investors have also adjusted their positions, while company insiders, CEO Daniel Faga and Director John P. Schmid, have sold shares. Despite missing EPS estimates but exceeding revenue expectations for its last quarter, AnaptysBio currently holds a "Moderate Buy" rating from analysts with a consensus price target of $81.82.
AnaptysBio Inc (ANAB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of AnaptysBio Inc's (ANAB) dividend and stock split history, noting that the company has not distributed any dividends over the past five years and has no recorded stock splits. It presents current stock performance data, including a market cap of $1.61 billion and a stock price of $55.580.
AnaptysBio Inc (ANAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article provides a revenue breakdown for AnaptysBio Inc (ANAB), detailing its business segments, regional revenue, and profit contribution. However, it states that the relevant data for these categories have not been disclosed by the company yet. The page also presents current stock information for AnaptysBio, including its market capitalization.
AnaptysBio, Inc. $ANAB Shares Purchased by 683 Capital Management LLC
683 Capital Management LLC increased its stake in AnaptysBio (NASDAQ:ANAB) by 18.5% in the fourth quarter, bringing its total holdings to 648,093 shares worth $31.42 million. Despite AnaptysBio missing EPS estimates in its recent earnings report, Wall Street analysts maintain a "Moderate Buy" rating with an average target price of $81.82. However, company insiders have been engaged in significant share selling in recent months.
AnaptysBio Inc (ANAB) Earnings Forecast: Future EPS & Revenue Growth Estimates
AnaptysBio Inc (ANAB) has an earnings forecast score of 8.73, ranking 72nd in its industry, with an average price target of $62.50 based on 11 analysts. The majority of analysts recommend a "Buy" for the stock, forecasting an expected revenue of $30.66M for the next quarter and an EPS of -$0.11.
AnaptysBio Inc (ANAB) Institutional Confidence
AnaptysBio Inc (ANAB) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 101.42%, indicating a quarter-over-quarter decrease of 37.03%. James Simons is the largest institutional shareholder, with other significant holders including EcoR1 Capital, LLC and Point72 Asset Management, L.P.
Director John Orwin of ANAPTYSBIO (NASDAQ: ANAB) settles 6,030 RSUs into common stock
ANAPTYSBIO director John A. Orwin converted 6,030 restricted stock units (RSUs) into common shares on June 15, 2026, increasing his direct holdings to 16,695 shares. This transaction involved no cash cost, sales, tax withholding, or gifts, as the RSUs vested 100% conditional on his continued service. The Form 4 filing details this equity compensation settlement.
AnaptysBio (ANAB) director acquires 6,030 shares via RSU vesting
AnaptysBio director John P. Schmid acquired 6,030 shares of common stock through the vesting of Restricted Stock Units (RSUs) on June 15, 2026, with no cash consideration. This transaction is a routine equity compensation event, not an open-market purchase or sale. Following this, Schmid directly holds 37,652 common shares, with no remaining RSU position reported.
Granahan Investment Management LLC Reduces Holdings in AnaptysBio, Inc. $ANAB
Granahan Investment Management LLC decreased its stake in AnaptysBio, Inc. by 14.8% in Q4, selling 21,918 shares but still holding 125,855 shares valued at $6.1 million. Despite this reduction, other institutional investors like Vanguard and Sofinnova increased their holdings. Analyst ratings for AnaptysBio are generally positive, with a "Moderate Buy" consensus and an average price target of $81.82, even though the company recently reported a wider-than-expected loss.
Dennis Mulroy sells multiple ANAB shares (NASDAQ: ANAB) across May–June 2026
Dennis Mulroy has filed a Form 144 with the SEC, disclosing multiple planned sales of AnaptysBio Inc. (NASDAQ: ANAB) common shares during May and June 2026. The sales involve both stock option exercises and open-market dispositions, with specific trade dates and share counts detailed in the filing. The filing indicates Morgan Stanley Smith Barney LLC as the executing broker for these transactions.
Sofinnova Investments Inc. Has $13.95 Million Stock Position in AnaptysBio, Inc. $ANAB
Sofinnova Investments Inc. significantly increased its stake in AnaptysBio, Inc. by 13.1% in the fourth quarter, now holding 287,690 shares valued at approximately $13.95 million. Despite recent insider sales by the CEO and a director, analysts maintain a "Moderate Buy" consensus for AnaptysBio, with an average target price of $81.82. The biotechnology company's stock opened at $59.51, reflecting a 6.1% rise, and has a market capitalization of $1.73 billion.
ANAB (NASDAQ: ANAB) affiliate files Form 144 to sell 20,000 shares
An affiliate of ANAPTYSBIO, INC (ANAB) has filed a Form 144 to sell 20,000 shares of common stock through a stock option exercise on June 15, 2026. The filing also details numerous recent dispositions by Dennis Mulroy in May and June 2026. This administrative resale notice provides transparency regarding the proposed sale and prior transactions.
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
AnaptysBio, Inc. (NASDAQ:ANAB) has received a consensus "Moderate Buy" rating from 13 analysts, with an average 12-month price target of $81.82. Despite reporting mixed quarterly results—revenue beating expectations but EPS missing—analysts anticipate a full fiscal year EPS of -$1.35. The article also notes recent insider share sales by a director and the CEO, alongside the company's authorized stock buyback plan.
ANAB (NASDAQ: ANAB) affiliate files Form 144 listing multiple share dispositions
An affiliate of ANAPTYSBIO, INC (ANAB) has filed a Form 144, indicating proposed sales of common stock by Dennis Mulroy. The filing details multiple dispositions planned between May 15, 2026, and June 12, 2026, including specific trade dates, share counts, and gross proceeds. This is a routine notice for proposed sales and does not confirm that the sales have already occurred.
Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright
HC Wainwright has issued its Q2 2026 earnings forecast for AnaptysBio (NASDAQ:ANAB), projecting a loss of $0.84 per share and reiterating a "Buy" rating with a $95 price target. Other analysts generally maintain a "Moderate Buy" consensus for the stock, with an average price target of $81.82, despite some recent downgrades to "Hold." AnaptysBio shares were up 4.1% and recently traded at $54.24, following a wider-than-expected quarterly loss but revenue beat.
Morgan Stanley (ANAB) plans 35,000-share sale; multiple insider dispositions listed
A Form 144 filing indicates that Morgan Stanley Smith Barney LLC intends to sell 35,000 shares of AnaptysBio, Inc. (ANAB) common stock on June 11, 2026, through a stock option exercise, valued at $1,848,750. The filing also details multiple past open-market dispositions by Dennis Mulroy between May 15, 2026, and June 10, 2026, involving sales ranging from 10,000 to over 22,987 shares with disclosed gross proceeds. The proposed sale and previous transactions are part of regulatory disclosures affecting transparency in the stock market.
[144] ANAPTYSBIO, INC SEC Filing
ANAPTYSBIO, INC (ANAB) affiliate Dennis Mulroy filed a Form 144, disclosing a 20,000-share stock option exercise on June 10, 2026, and multiple sales of common stock between May 15 and June 9, 2026. The filing details the number of shares sold and the gross proceeds for each transaction. This Form 144 indicates proposed and completed dispositions by an affiliate.
ANAB Assumed by HC Wainwright & Co. -- Rating Set to Buy
HC Wainwright & Co. has initiated coverage of AnaptysBio (ANAB) with a Buy rating and a price target of $95.00, citing the company's clinical trials and product development. GuruFocus also indicates ANAB is undervalued by 18.8% with a GF Value™ of $63.59, despite a moderate GF Score™ of 63/100 and recent insider selling activity. Investors are advised to research thoroughly due to mixed signals regarding profitability and insider confidence.
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating
H.C. Wainwright has initiated coverage on AnaptysBio Inc. (NASDAQ:ANAB) with a buy rating and a price target of $95.00, following the spinoff of First Tracks Bio. The firm highlights AnaptysBio's focus on royalty-bearing assets, aggressive stock buybacks, and a projected turn to profitability in fiscal 2026. The stock's impressive 223% return over the past year is also noted.
AnaptysBio, Inc. $ANAB Shares Acquired by BNP Paribas Financial Markets
BNP Paribas Financial Markets significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the fourth quarter, acquiring an additional 59,160 shares to own a total of 164,823 shares valued at $7,991,000. This move is part of broader institutional investment changes in AnaptysBio, with other firms also adjusting their positions. Despite some insider selling, the company has an average analyst rating of "Moderate Buy" with a consensus target price of $79.18 and recently initiated a substantial share repurchase plan.
ANAB (ANAB) insider files Form 144 to sell 20,000 shares via option exercise
A Form 144 filing indicates that an insider at ANAB (ANAPTYSBIO, INC), Dennis Mulroy, plans to sell 20,000 shares obtained through a stock option exercise on June 9, 2026, with the proceeds going to the issuer. The filing also details multiple previous share dispositions by Mulroy in May and June 2026, including sales of 21,987 shares and 22,491 shares. These are routine transparency disclosures, and further confirmation of completed transactions would typically appear in subsequent filings or Form 4s.
ANAB (NASDAQ: ANAB) Form 144 shows Dennis Mulroy selling multiple lots
A recently filed Form 144 by Anaptysbio, Inc. (NASDAQ: ANAB) indicates that Dennis Mulroy, an affiliate, is selling multiple lots of common stock. The filing details various transactions from May to June 2026, including a significant sale of 22,491 shares for over $1.15 million on June 5, 2026, alongside several 20,000-share entries. Additionally, the document mentions restricted stock grants and a 13,910 share stock option exercise by the issuer on June 8, 2026.
ANAB (NASDAQ: ANAB) director reports multiple stock-option sales, dates listed
A director at AnaptysBio, Inc. (NASDAQ: ANAB), Dennis Mulroy, filed a Form 144 detailing multiple proposed dispositions of common stock through stock option exercises and cash settlements. The filing indicates sales activity between May 15, 2026, and June 5, 2026, including 20,000 shares sold on June 4, 2026, for over $1 million. This routine reporting provides transparency on insider stock sales without indicating new material corporate events.
ANAB insider resale filed: 20,000 shares via option (ANAB)
An affiliate of ANAPTYSBIO, INC (ANAB) has filed a Form 144 proposing the sale of 20,000 shares of common stock, acquired via a stock option exercise, with the transaction facilitated by Morgan Stanley Smith Barney LLC. The proposed sale date is June 4, 2026. The filing also details multiple past sales by Dennis Mulroy in May-June 2026, including 15,000 shares on May 29, 2026, and 15,467 shares on May 21, 2026, along with reported proceeds for those transactions.
AnaptysBio (NASDAQ:ANAB) Lowered to "Hold" Rating by Zacks Research
Zacks Research has downgraded AnaptysBio (NASDAQ:ANAB) from a "strong-buy" to a "hold" rating, despite other analysts maintaining a more positive outlook, resulting in a consensus "Moderate Buy" rating with an average price target of $79.18. The company recently missed earnings per share estimates but exceeded revenue forecasts. Insider selling, including by the CEO and a director, has been reported, although insiders still collectively own 33.50% of the stock.
20,000 ANAB Shares Registered; Dennis Mulroy Sold Multiple Lots (ANAB)
A Form 144 filing for AnaptysBio, Inc. (ANAB) has registered 20,000 common shares for sale on June 3, 2026, through a stock option exercise for cash. The filing also detailed multiple prior sales by Dennis Mulroy throughout May and June 2026, collectively representing many tens of thousands of shares, including 15,000 shares sold for $834,903.00 on May 29, 2026. This activity is considered a routine disclosure under Section 144, indicating an affiliate sale and documenting recent dispositions.
Affiliate of ANAB (NASDAQ: ANAB) to sell 7,691 shares after option exercise
An affiliate of ANAPTYSBIO, INC (NASDAQ: ANAB), Dennis Mulroy, has filed a Form 144 to sell 7,691 shares of the company's common stock. The proposed sale is scheduled for June 1, 2026, and results from a stock option exercise, with proceeds expected in cash. This filing also discloses several other dispositions made by Mulroy in May 2026.
ANAB - AnaptysBio Inc Stock Price and Quote
This article provides a comprehensive overview of AnaptysBio Inc. (ANAB) stock, including its current price, financial data, analyst ratings, and recent news. It details insider transactions and company information, serving as a snapshot of the company's financial health and market perception.
ANAB proposes sale of 15,000 shares (NASDAQ: ANAB)
ANAPTYSBIO, INC (ANAB) has filed a Form 144, indicating a proposed sale of 15,000 common shares through a stock option exercise on May 29, 2026. The filing also details multiple recent cash sales by Dennis Mulroy, including 10,264 shares sold on May 28, 2026, for gross proceeds of $594,671.20, and other significant sales throughout May. This notice serves to inform the market about potential controlled resales of the company's stock.
AnaptysBio posts Form 8937 on tax treatment of First Tracks spin-off dividend
AnaptysBio has filed Form 8937 with the IRS to detail the tax treatment of the First Tracks spin-off dividend for its stockholders. This form will be available on the Investors section of its website and provides guidance on how this dividend is treated and how tax basis changes are determined. The company advises stockholders to consult their tax advisors as the information is for informational purposes only and not legal or tax advice.
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB)
AnaptysBio (NASDAQ: ANAB) has released tax information for its stockholders regarding the dividend received from the spin-off of First Tracks Biotherapeutics, Inc. The company filed IRS Form 8937, which explains the tax treatment of the dividend and how stockholders should determine their adjusted tax basis. AnaptysBio advises shareholders to consult their personal tax advisors as the provided information is for informational purposes only and not tax advice.
